Page 1

■ CARMAT PRESS RELEASE CARMAT reports its 2021 half - year results and issues an update on its latest progress and main strategic objectives 6 AesonⓇ artificial hearts marketed to date Enrollment of the first cohort of 3 patients in the EFS¹ in the USA finalized Cash position of € 58 million at June 30 , 2021 , covering the Company's activities through to mid - 2022 Videoconference with Stéphane Piat today at 5 pm Paris time Paris , September 15 , 2021 – 7:00 am CEST CARMAT ( FR0010907956 , ALCAR ) , the designer and developer of the world's most advanced total artificial heart , aiming to provide a therapeutic alternative to people suffering from end - stage biventricular heart failure , today reports its results for the first half of the year to June 30 , 20212 and issues an update on its latest progress and main strategic objectives . Stéphane Piat , Chief Executive Officer of CARMAT , commented : “ Following the granting of CE marking in December 2020 , CARMAT dedicated most of its resources to preparing the commercial launch in Europe , initiating the EFS in the US and strengthening its supply chain . Despite the constraints associated with the COVID - 19 pandemic , CARMAT achieved key milestones : since July , 6 patients in leading German and Italian hospitals did benefit from Aeson® , the world's first physiological artificial heart , in a commercial setting . CARMAT also successfully completed the enrollment of the first cohort of 3 patients in the EFS study , with some of the largest and renowned American cardiology centers such as Duke University Hospital , paving the way to the evaluation of our device in the US , the world's largest medical device market . The very positive feedback regarding the implantations of AesonⓇ in both commercial and clinical trials settings is further demonstrating our confidence that our device represents a valid alternative to heart transplants . We anticipate that around a dozen European centers , primarily in Germany , will be commercially active by the end of 2021. In order to support this momentum , CARMAT has also been working on ramping up its production activities , which should allow the company to manufacture Aeson® prostheses at an increasing pace in order to appropriately supply hospitals that would like to offer our unique technology to their patients " . 1 Early Feasibility Study 2 First - half results were approved by the Board on September 13 , 2021 and have been the subject of a limited review by the statutory auditors . The 2021 half - year financial report was published today and is available on the Company's website . 1/6